The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
暂无分享,去创建一个
D. White | T. Hughes | S. Branford | L. Eadie | V. Saunders | T. Hughes | D. White
[1] J. Cayuela,et al. Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib , 2017, Leukemia.
[2] Hans Bitter,et al. The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 , 2017, Nature.
[3] D. Yeung,et al. A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells , 2016 .
[4] M. Heinrich,et al. Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy , 2016 .
[5] D. White,et al. ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines , 2016, PloS one.
[6] W. Sellers,et al. ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia , 2014 .
[7] T. P. Hughes,et al. Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib , 2014, Clinical pharmacology and therapeutics.
[8] T. Clackson,et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.
[9] Lukasz Skóra,et al. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors , 2013, Proceedings of the National Academy of Sciences.
[10] R. Larson,et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. , 2013, Blood.
[11] I. Dusanter-Fourt,et al. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. , 2013, Cancer research.
[12] D. White,et al. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2 , 2013, Leukemia & lymphoma.
[13] P. Szankasi,et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. , 2013, Blood.
[14] I. Flinn,et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.
[15] D. White,et al. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways , 2011, Leukemia & lymphoma.
[16] R. Moriggl,et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. , 2011, Blood.
[17] J. Mestan,et al. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. , 2010, Biochimica et biophysica acta.
[18] H. Kantarjian,et al. Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib , 2010, Clinical pharmacology and therapeutics.
[19] John T. Powers,et al. Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.
[20] T. Clackson,et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.
[21] Rocco Piazza,et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Kantarjian,et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. , 2008, Blood.
[23] B. Turcq,et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. , 2008, Cancer research.
[24] Wolfgang Jahnke,et al. Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib*♦ , 2008, Journal of Biological Chemistry.
[25] J. Melo,et al. Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.
[26] J. Apperley. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.
[27] M. Deininger,et al. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.
[28] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[29] H. Kantarjian,et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate , 2006, Leukemia.
[30] J. Mestan,et al. Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.
[31] Mariël Brok,et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.
[32] A. Racine‐Poon,et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] G. Superti-Furga,et al. A Myristoyl/Phosphotyrosine Switch Regulates c-Abl , 2003, Cell.
[34] G. Superti-Furga,et al. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.
[35] L. Campbell,et al. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. , 2002, Cancer genetics and cytogenetics.
[36] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[37] R. Herrmann,et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.
[38] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[39] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[40] Branford,et al. Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics , 1999, British journal of haematology.
[41] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[42] D. White,et al. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment , 2017, Leukemia.
[43] J. Radich,et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study , 2013, Leukemia.
[44] M. Gordon. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia , 2010 .
[45] M. Gordon. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .